Indian authority withdraws patent for interferon granted to Roche

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7499 (Published 6 November 2012)
Cite this as: BMJ 2012;345:e7499

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Meera Kay
  1. 1Bangalore

India’s Intellectual Property Appellate Board has repealed the patent granted to the drug company Roche for pegylated interferon alfa-2a (Pegasys), which is used to treat hepatitis C.

The board’s order represents a watershed in the history of patents in India and a victory for patients’ groups fighting to widen access to drugs.

“This is India’s first successful post-grant opposition case,” said Eldred Tellis, director of the Sankalp Rehabilitation Trust, a non-governmental organisation that had challenged the patent. “And it is significant because the patent granted to Roche in 2006 was the first product patent on a medicine in India after …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL